JP2005500831A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005500831A5 JP2005500831A5 JP2003505346A JP2003505346A JP2005500831A5 JP 2005500831 A5 JP2005500831 A5 JP 2005500831A5 JP 2003505346 A JP2003505346 A JP 2003505346A JP 2003505346 A JP2003505346 A JP 2003505346A JP 2005500831 A5 JP2005500831 A5 JP 2005500831A5
- Authority
- JP
- Japan
- Prior art keywords
- factor viii
- variant
- polypeptide
- nucleic acid
- factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010054218 Factor VIII Proteins 0.000 claims 24
- 102000001690 Factor VIII Human genes 0.000 claims 24
- 235000018417 cysteine Nutrition 0.000 claims 24
- 229960000301 factor viii Drugs 0.000 claims 24
- 102000039446 nucleic acids Human genes 0.000 claims 21
- 108020004707 nucleic acids Proteins 0.000 claims 21
- 150000007523 nucleic acids Chemical class 0.000 claims 21
- 229920001184 polypeptide Polymers 0.000 claims 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims 20
- 238000000034 method Methods 0.000 claims 19
- 241000124008 Mammalia Species 0.000 claims 14
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 12
- 150000001945 cysteines Chemical class 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 108010014172 Factor V Proteins 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 10
- 102100027378 Prothrombin Human genes 0.000 claims 9
- 108010094028 Prothrombin Proteins 0.000 claims 9
- 229940039716 prothrombin Drugs 0.000 claims 9
- 239000013598 vector Substances 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 8
- 239000002773 nucleotide Substances 0.000 claims 8
- 125000003729 nucleotide group Chemical group 0.000 claims 8
- 208000009292 Hemophilia A Diseases 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 210000002845 virion Anatomy 0.000 claims 4
- 208000031220 Hemophilia Diseases 0.000 claims 2
- 208000032843 Hemorrhage Diseases 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 208000034158 bleeding Diseases 0.000 claims 2
- 230000000740 bleeding effect Effects 0.000 claims 2
- 230000023555 blood coagulation Effects 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 230000000087 stabilizing effect Effects 0.000 claims 2
- 102000004506 Blood Proteins Human genes 0.000 claims 1
- 108010017384 Blood Proteins Proteins 0.000 claims 1
- 108010080865 Factor XII Proteins 0.000 claims 1
- 102000000429 Factor XII Human genes 0.000 claims 1
- 108010043026 HGF activator Proteins 0.000 claims 1
- 102100031465 Hepatocyte growth factor activator Human genes 0.000 claims 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 1
- 102100039238 Hyaluronan-binding protein 2 Human genes 0.000 claims 1
- 101710163637 Hyaluronan-binding protein 2 Proteins 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 230000002785 anti-thrombosis Effects 0.000 claims 1
- 238000006664 bond formation reaction Methods 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 102000057593 human F8 Human genes 0.000 claims 1
- 229960000900 human factor viii Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29857801P | 2001-06-14 | 2001-06-14 | |
| PCT/US2002/019017 WO2002103024A2 (en) | 2001-06-14 | 2002-06-14 | Stabilized proteins with engineered disulfide bonds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008124202A Division JP2008271975A (ja) | 2001-06-14 | 2008-05-12 | 操作されたジスルフィド結合を有する安定化蛋白質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005500831A JP2005500831A (ja) | 2005-01-13 |
| JP2005500831A5 true JP2005500831A5 (enExample) | 2006-01-05 |
| JP4361786B2 JP4361786B2 (ja) | 2009-11-11 |
Family
ID=23151124
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003505346A Expired - Fee Related JP4361786B2 (ja) | 2001-06-14 | 2002-06-14 | 操作されたジスルフィド結合を有する安定化蛋白質 |
| JP2008124202A Pending JP2008271975A (ja) | 2001-06-14 | 2008-05-12 | 操作されたジスルフィド結合を有する安定化蛋白質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008124202A Pending JP2008271975A (ja) | 2001-06-14 | 2008-05-12 | 操作されたジスルフィド結合を有する安定化蛋白質 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7205278B2 (enExample) |
| EP (2) | EP1421539B1 (enExample) |
| JP (2) | JP4361786B2 (enExample) |
| AU (1) | AU2002310438B2 (enExample) |
| CA (1) | CA2450732A1 (enExample) |
| DE (1) | DE60234193D1 (enExample) |
| ES (1) | ES2331909T3 (enExample) |
| WO (1) | WO2002103024A2 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002103024A2 (en) * | 2001-06-14 | 2002-12-27 | The Scripps Research Institute | Stabilized proteins with engineered disulfide bonds |
| EP1502921A1 (en) * | 2003-07-29 | 2005-02-02 | ZLB Behring GmbH | Recombinant mutated human factor VIII (FVIII) with improved stability |
| AU2004296768B2 (en) * | 2003-12-03 | 2010-06-24 | University Of Rochester | Recombinant factor VIII having increased specific activity |
| US20060019893A1 (en) * | 2004-07-02 | 2006-01-26 | Genentech, Inc. | Factor VIIa variants |
| KR101483917B1 (ko) * | 2004-11-12 | 2015-01-16 | 바이엘 헬스케어 엘엘씨 | Ｆｖｉｉｉ의 부위 지향 변형 |
| WO2006108590A1 (en) * | 2005-04-14 | 2006-10-19 | Csl Behring Gmbh | Modified coagulation factor viii with enhanced stability and its derivates |
| GB0514779D0 (en) * | 2005-07-19 | 2005-08-24 | Celltech R&D Ltd | Biological products |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| US20100144620A1 (en) * | 2006-11-16 | 2010-06-10 | Crucell Holland B.V. | Complementation of factor xi deficeincy by factor v mutants |
| KR101542752B1 (ko) | 2006-12-22 | 2015-08-10 | 체에스엘 베링 게엠베하 | 연장된 생체내 반감기를 갖는 변형된 응고 인자 |
| KR20100113478A (ko) * | 2007-11-01 | 2010-10-21 | 유니버시티 오브 로체스터 | 증가된 안정성을 갖는 재조합 인자 ⅴⅰⅰⅰ |
| RU2528855C2 (ru) | 2008-06-24 | 2014-09-20 | Цсл Беринг Гмбх | Модифицированный фактор виллебранда с удлиненным полупериодом существования in vivo, его применения и способы получения |
| JP5816097B2 (ja) * | 2009-01-22 | 2015-11-18 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 安定な成長ホルモン化合物 |
| TW201127957A (en) * | 2009-10-30 | 2011-08-16 | Agres Ltd | Modified oil encapsulating proteins and uses thereof |
| AU2011208620B2 (en) | 2010-01-22 | 2015-04-16 | Novo Nordisk Health Care Ag | Stable growth hormone compounds |
| SI2525834T1 (sl) | 2010-01-22 | 2019-10-30 | Novo Nordisk Healthcare Ag | Rastni hormoni s podaljšano in vivo učinkovitostjo |
| JP2013532176A (ja) * | 2010-07-15 | 2013-08-15 | ノヴォ ノルディスク アー／エス | 安定化させた第ｖｉｉｉ因子バリアント |
| WO2012010516A1 (en) * | 2010-07-22 | 2012-01-26 | Novo Nordisk Health Care Ag | Growth hormone conjugates |
| EP2814502B1 (en) | 2012-02-15 | 2017-09-13 | CSL Behring GmbH | Von willebrand factor variants having improved factor viii binding affinity |
| CA2873511A1 (en) | 2012-05-17 | 2013-11-21 | Ra Pharmaceuticals, Inc. | Peptide and peptidomimetic inhibitors |
| KR20150132449A (ko) * | 2013-03-15 | 2015-11-25 | 바이엘 헬스케어 엘엘씨 | 재조합 인자 viii 제제 |
| CN105120887A (zh) | 2013-04-05 | 2015-12-02 | 诺和诺德保健股份有限公司 | 生长激素化合物制剂 |
| DK2796145T3 (da) | 2013-04-22 | 2018-01-29 | Csl Ltd | Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro |
| CA2929671A1 (en) * | 2013-11-04 | 2015-05-07 | The Regents Of The University Of California | Therapy for treatment or prevention of conditions associated with bleeding or hypocoagulation |
| US10253088B2 (en) | 2014-07-02 | 2019-04-09 | CSL Behring Lengnau AG | Modified von Willebrand Factor |
| CA2978374A1 (en) | 2015-03-06 | 2016-09-15 | Csl Behring Recombinant Facility Ag | Modified von willebrand factor having improved half-life |
| KR20180012303A (ko) | 2015-05-22 | 2018-02-05 | 체에스엘 베링 리컴비넌트 퍼실리티 아게 | 변형된 폰 빌레브란트 인자의 제조 방법 |
| EP3297656B1 (en) | 2015-05-22 | 2020-01-08 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for treating hemophilia |
| CN104974228B (zh) * | 2015-06-15 | 2017-10-17 | 四川合泰新光生物科技有限公司 | 一种小分子多肽zy4及其应用 |
| CA3010720A1 (en) | 2016-01-07 | 2017-07-13 | Csl Behring Recombinant Facility Ag | Mutated truncated von willebrand factor |
| DK3400238T3 (da) | 2016-01-07 | 2021-07-26 | CSL Behring Lengnau AG | Muteret von willebrand faktor |
| SG10201912360SA (en) | 2016-11-11 | 2020-02-27 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for treating hemophilia |
| US11890327B2 (en) | 2016-11-11 | 2024-02-06 | CSL Behring Lengnau AG | Truncated von Willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
| JP7524071B2 (ja) * | 2018-04-19 | 2024-07-29 | スティヒティング ブイユー | タンパク質のマクロ環化 |
| EP3810647A4 (en) * | 2018-04-26 | 2022-08-17 | The University of North Carolina at Chapel Hill | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEMOPHILIA |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5214033A (en) * | 1983-03-31 | 1993-05-25 | Scripps Clinic & Research Foundation | Factor VIII coagulant polypeptides |
| US4757006A (en) * | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| SE8501050D0 (sv) | 1985-03-05 | 1985-03-05 | Kabivitrum Ab | Biologically active fragments of human antihemophilic factor and method for preparation thereof |
| WO1986006101A1 (en) | 1985-04-12 | 1986-10-23 | Genetics Institute, Inc. | Novel procoagulant proteins |
| US5198349A (en) | 1986-01-03 | 1993-03-30 | Genetics Institute, Inc. | Method for producing factor VIII:C and analogs |
| US5250421A (en) | 1986-01-03 | 1993-10-05 | Genetics Institute, Inc. | Method for producing factor VIII:C-type proteins |
| US5422260A (en) * | 1986-05-29 | 1995-06-06 | Genetics Institute, Inc. -Legal Affairs | Human factor VIII:c muteins |
| US4853871A (en) * | 1987-04-06 | 1989-08-01 | Genex Corporation | Computer-based method for designing stablized proteins |
| US5449759A (en) * | 1987-05-16 | 1995-09-12 | Somatogen, Inc. | Hemoglobins with intersubunit desulfide bonds |
| US5827821A (en) * | 1987-12-10 | 1998-10-27 | The Burnham Institute | Conformationally stabilized cell adhesion peptides |
| US5009889A (en) * | 1987-12-31 | 1991-04-23 | Oklahoma Medical Research Foundation | Treatment of dysfunctional vascular endothelium using activated protein C |
| US4852871A (en) * | 1988-12-02 | 1989-08-01 | John Perko | Hand exercise device |
| US5082767A (en) * | 1989-02-27 | 1992-01-21 | Hatfield G Wesley | Codon pair utilization |
| US5610137A (en) * | 1990-12-20 | 1997-03-11 | The Uab Research Foundation | Transgenic, cross-linked hemoglobin |
| US5661008A (en) * | 1991-03-15 | 1997-08-26 | Kabi Pharmacia Ab | Recombinant human factor VIII derivatives |
| US5114148A (en) * | 1991-07-09 | 1992-05-19 | Liu Ming Zen | Puzzle device |
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| US5364771A (en) | 1992-04-07 | 1994-11-15 | Emory University | Hybrid human/porcine factor VIII |
| US6180371B1 (en) | 1996-06-26 | 2001-01-30 | Emory University | Modified factor VIII |
| US5859204A (en) | 1992-04-07 | 1999-01-12 | Emory University | Modified factor VIII |
| US5453937A (en) * | 1993-04-28 | 1995-09-26 | Immunex Corporation | Method and system for protein modeling |
| US5747654A (en) * | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
| DE4418635C2 (de) * | 1994-05-27 | 1997-07-24 | Immuno Ag | Pharmazeutische Zusammensetzung zur Vorbeugung und Behandlung von Blutgerinnungsstörungen |
| US5681746A (en) * | 1994-12-30 | 1997-10-28 | Chiron Viagene, Inc. | Retroviral delivery of full length factor VIII |
| US5543149A (en) * | 1995-03-01 | 1996-08-06 | Rubin; Stan M. | Treatment for insect bites |
| US5935568A (en) | 1995-05-18 | 1999-08-10 | National Jewish Medical & Research Center | Gene therapy for effector cell regulation |
| US5910481A (en) * | 1995-11-13 | 1999-06-08 | Immuno Ag | Hybrid proteins with modified activity |
| US20040092442A1 (en) * | 1996-04-24 | 2004-05-13 | University Of Michigan | Inactivation resistant factor VIII |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US6262238B1 (en) * | 1997-01-14 | 2001-07-17 | Roche Diagnostic, Gmbh | Process for modifying the stability of antibodies |
| DE69836206T2 (de) | 1997-02-07 | 2007-08-23 | Merck & Co., Inc. | Synthetische hiv gag gene |
| US6358703B1 (en) * | 1998-12-10 | 2002-03-19 | Bayer Corporation | Expression system for factor VIII |
| WO2002103024A2 (en) * | 2001-06-14 | 2002-12-27 | The Scripps Research Institute | Stabilized proteins with engineered disulfide bonds |
-
2002
- 2002-06-14 WO PCT/US2002/019017 patent/WO2002103024A2/en not_active Ceased
- 2002-06-14 US US10/172,712 patent/US7205278B2/en not_active Expired - Fee Related
- 2002-06-14 DE DE60234193T patent/DE60234193D1/de not_active Expired - Lifetime
- 2002-06-14 CA CA002450732A patent/CA2450732A1/en not_active Abandoned
- 2002-06-14 JP JP2003505346A patent/JP4361786B2/ja not_active Expired - Fee Related
- 2002-06-14 ES ES02737516T patent/ES2331909T3/es not_active Expired - Lifetime
- 2002-06-14 AU AU2002310438A patent/AU2002310438B2/en not_active Ceased
- 2002-06-14 EP EP02737516A patent/EP1421539B1/en not_active Expired - Lifetime
- 2002-06-14 EP EP09159506A patent/EP2110385A1/en not_active Withdrawn
-
2007
- 2007-01-25 US US11/627,197 patent/US7928199B2/en not_active Expired - Fee Related
-
2008
- 2008-05-12 JP JP2008124202A patent/JP2008271975A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005500831A5 (enExample) | ||
| JP2655752B2 (ja) | 組換えヒト第▲ｖｉｉｉ▼因子誘導体 | |
| Ribes et al. | Fibrin induces release of von Willebrand factor from endothelial cells. | |
| US7928199B2 (en) | Stabilized proteins with engineered disulfide bonds | |
| NO20024475L (no) | Produksjon av rekombinante blodkoagulasjonsfaktorer i humane cellelinjer | |
| JP2003530093A5 (enExample) | ||
| ATE435232T1 (de) | Nukleotid- und proteinsequenzen von nogo-genen und darauf beruhende methoden | |
| US20120164111A1 (en) | Novel post-translational fibrinogen variants | |
| JP2003530070A5 (enExample) | ||
| JPH05502161A (ja) | 組換えヒト８因子誘導体 | |
| RU2007105677A (ru) | Модифицированные витамин к-зависимые полипептиды | |
| JP2005538932A5 (enExample) | ||
| JP2549224B2 (ja) | 組換えにより産生される血液因子及びその血液因子の発現方法並びにその方法に使用されるワクシニアウイルス組換え体 | |
| US5262309A (en) | Terminal modifications of tumor necrosis factor | |
| JP2004534503A5 (enExample) | ||
| NO20013608L (no) | DNA-klon for human vevsfaktorinhibitor | |
| ES2235153T3 (es) | Dominios terapeuticos del factor de von willebrand. | |
| SK130696A3 (en) | Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors | |
| CN114901686A (zh) | 因子viii多肽 | |
| JPH11507542A (ja) | プロトロンビン誘導体 | |
| WO1999040115A3 (en) | COMPOSITIONS AND METHODS TO INHIBIT FORMATION OF THE C5b-9 COMPLEX OF COMPLEMENT | |
| Gohda et al. | Human hepatocyte growth factor in blood of patients with fulminant hepatic failure: basic aspects | |
| Lawn | How often has Lp (a) evolved? | |
| Black | Drug products of recombinant DNA technology | |
| Kotlın et al. | Fibrinogen Šumperk II: dysfibrinogenemia in an individual with two coding mutations |